Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01714804 · ClinicalTrials.gov registry record · NA
Efficacy and Safety of Integra Accell Evo3 DBM in Instrumented Lumbar Spine Fusion
A NA study, sponsored by SeaSpine.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT01714804: Completed NA study, sponsored by SeaSpine.
NCT01714804 is a NA study that has completed, run by SeaSpine. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01714804, a NA study, has completed, sponsored by SeaSpine.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The objective of this study is to prospectively evaluate the performance of Integra Accell Evo3 Demineralized Bone Matrix as an adjunct for instrumented lumbar spine fusion with a retrospective comparison to a historical patient cohort.
Primary Outcome
Assessment of fusion in the posterolateral space was performed using by X-ray and/or CT. Assessment was performed by the operating surgeon blinded towards patient. Each spinal level was graded separately
Interventions
- DEVICE Accell Evo3 Prospective Use
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2012-08 |
| Est. Completion | 2016-10 |
| Phase | NA |
What the finished NCT01714804 record still lists
NCT01714804 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Accell Evo3 Prospective Use is the first listed.
NCT01714804 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01714804 about?
NCT01714804 is a clinical study titled "Efficacy and Safety of Integra Accell Evo3 DBM in Instrumented Lumbar Spine Fusion". The objective of this study is to prospectively evaluate the performance of Integra Accell Evo3 Demineralized Bone Matrix as an adjunct for instrumented lumbar spine fusion with a retrospective comparison to a historical patient cohort.
What is the current status of trial NCT01714804?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2012-08. Estimated completion is 2016-10.
What interventions are being tested in trial NCT01714804?
The interventions under investigation include: Accell Evo3 Prospective Use (DEVICE).
Who is sponsoring clinical trial NCT01714804?
This trial is sponsored by SeaSpine, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01714804's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia